For the Inventor, By the Inventor

Enter assignee name

South San Francisco, CA, United States of America

Theravance, Inc.

USPTO Granted Patents = 386

% Expired Patents = 39.9

CIPO Patents = 25

EPO Patents = 37

Trademarks = 6

Forward Citations = 4,492

Loading Chart...

Loading Chart...

117 inventors (with patents filed for the assignee):

Mathai Mammen (92 out of 104 patents)

Paul Ross Fatheree (90 out of 144 patents)

YongQi Mu (67 out of 95 patents)

4. Seok-Ki Choi (63 out of 76 patents)

5. Daniel D Long (60 out of 104 patents)

6. Yu-Hua Ji (56 out of 58 patents)

7. Craig Husfeld (51 out of 85 patents)

8. Daniel Marquess (51 out of 58 patents)

9. Martin Sheringham Linsell (50 out of 82 patents)

10. Adam D Hughes (46 out of 136 patents)

11. Li Li (40 out of 55 patents)

12. Roland Gendron (40 out of 75 patents)

13. Robert Murray McKinnell (38 out of 73 patents)

14. Edmund J Moran (35 out of 48 patents)

15. Michael Robert Leadbetter (35 out of 66 patents)

Core Competencies:

Biphenyl Compounds

Antihypertensive Agents

Serotonin Reuptake Inhibitors

Mu Opioid Receptor Antagonists

Neprilysin Inhibitors

Quaternary Ammonium Compounds

Aminotetralin Derivatives

Glycopeptide Antibiotics

Dual-acting Agents

Crystalline Forms

Process Preparation

Alkoxyimidazol Compounds

386 patents: Sort by Forward Citations

1. 8754225 - Process for preparing a biphenyl-2-ylcarbamic acid (2014-06-17),

2. 8754223 - Crystalline form of a biphenyl compound (2014-06-17),

3. 8735625 - Dual-acting antihypertensive agents (2014-05-27),

4. 8729119 - Serotonin reuptake inhibitors (2014-05-20),

5. 8716313 - Crystalline forms of a biphenyl compound (2014-05-06),

6. 8703791 - 3-carboxypropyl-aminotetralin derivatives and related compounds as mu opioid receptor antagonists (2014-04-22),

7. 8697724 - Crystalline oxalate salts of a diamide compound (2014-04-15),

8. 8691868 - Neprilysin inhibitors (2014-04-08),

9. 8686184 - Neprilysin inhibitors (2014-04-01),

10. 8664254 - Dual-acting imidazole antihypertensive agents (2014-03-04),

11. 8664242 - 8-azabicyclo[3.2.1]octane compounds as mu opioid receptor antagonists (2014-03-04),

12. 8664227 - Dual-acting thiophene, pyrrole, thiazole and furan antihypertensive agents (2014-03-04),

13. 8658691 - Crystalline forms of a 3-[2-methanesulfonyl-1-(4-trifluoromethyl-phenoxy)ethyl]pyrrolidine compound (2014-02-25),

14. 8658671 - Crystalline form of a quinolinone-carboxamide compound (2014-02-25),

15. 8637676 - Dual-acting benzoimidazole antihypertensive agents (2014-01-28),

Theravance, Inc. is a biopharmaceutical company focused on the discovery, development, and commercialization of innovative medicines. They aim to transform the lives of patients suffering from serious illnesses by delivering therapeutics that address significant unmet medical needs. Theravance specializes in developing treatments for respiratory diseases, gastrointestinal disorders, and infectious diseases.

This text is generated by artificial intelligence and may not be accurate.

Company Badge

USPTO Data Jan 1 1976 - Sep 15 2026

Theravance, Inc.

386 Patents

#3 in South San Francisco, CA

#255 in California

#1,193 in US

#2,389 in the World

South San Francisco, CA, United States of America

Theravance, Inc.

Forward Citations = 4,492

117 inventors:

Mathai Mammen (92 out of 104 patents)

Paul Ross Fatheree (90 out of 144 patents)

YongQi Mu (67 out of 95 patents)

4. Seok-Ki Choi (63 out of 76 patents)

5. Daniel D Long (60 out of 104 patents)

Please report any incorrect information to [email protected]

Loading…